StockData

Kazia Therapeutics vs Lyell Immunopharma

KZIA and LYEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KZIA and LYEL compare

Lyell Immunopharma grew revenue faster over the last twelve months (−55.0% versus −98.2% for Kazia Therapeutics).

Kazia Therapeutics keeps more of each dollar of sales as profit, with a net margin of −49291% compared with −920285% at Lyell Immunopharma.

Lyell Immunopharma scores higher on the StockData Score (6 against 1 for Kazia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKZIALYEL
Size and price
Market cap–$335M
Share price$5.31$13.67
Change, 1 year−15.3%−19.3%
Change, 5 years−98.9%−92.7%
Beta (5Y)4.081.37
Employees14–
StockData Score
Total score16 (better)
Valuation score01 (better)
Growth score00
Performance score00
Health score15 (better)
Dividend score00
Valuation
P/S–12407×
P/B–1.4×
FCF yield–−40.0%
Growth
Revenue growth (TTM)−98.2%−55.0% (better)
Revenue growth, 5Y average–−65.9%
Profitability
Operating margin–−949981%
Net margin−49291% (better)−920285%
FCF margin–−496189%
Return on equity–−93.3%
Return on invested capital–−782%
Financial health
Debt / equity–0.00
Current ratio2.875.36 (better)
Altman Z-score–−7.05
Piotroski F-score22
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.45%48.9%
Held by insiders0.29%45.0%
Insider net buying, 12 months–$74.4M
Superinvestors holding1–
Short interest, % of float–10.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.